CD79B and MYD88 Mutations in Splenic Marginal Zone Lymphoma
Author(s) -
Gunhild Trøen,
Abdirashid Warsame,
Jan Delabie
Publication year - 2013
Publication title -
isrn oncology
Language(s) - English
Resource type - Journals
eISSN - 2090-567X
pISSN - 2090-5661
DOI - 10.1155/2013/252318
Subject(s) - splenic marginal zone lymphoma , cancer research , gene , biology , point mutation , mutation , lymphoma , genetics , immunology , b cell , antibody
The mutation status of genes involved in the NF- κ B signaling pathway in splenic marginal zone lymphoma was examined. DNA sequence analysis of four genes was performed: CD79A, CD79B, CARD11, and MYD88 that are activated through BCR signaling or Toll-like and interleukin signaling. A single point mutation was detected in the CD79B gene (Y196H) in one of ten SMZL cases. Additionally, one point mutation was identified in the MYD88 gene (L265P) in another SMZL case. No mutations were revealed in CD79A or CARD11 genes in these SMZL cases. Neither were mutations detected in these four genes studied in 13 control MZL samples. Interestingly, the two cases with mutations of CD79B and MYD88 showed increased numbers of immunoblasts spread among the smaller and typical marginal zone lymphoma cells. Although SMZL shows few mutations of NF- κ B signaling genes, our results indicate that the presence of these mutations is associated with a higher histological grade.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom